USL-311
- Generic Name
- USL-311
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N6O
- CAS Number
- 1373268-67-7
- Unique Ingredient Identifier
- 2BTG5MX2Q2
- Background
USL-311 is under investigation in clinical trial NCT02765165 (Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)).
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Phase 1
Terminated
- Conditions
- Relapsed/Recurrent GBM (Phase 2)Solid Tumors (Phase 1)
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Proximagen, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02765165
- Locations
- 🇺🇸
University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath